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Strengths and limitations of this study
 ► This study assessed a large set of evidence- based 
quality indicators (QIs) for primary healthcare in the 
Swiss context.
 ► The predictive value of each QI on hospitalisation 
risk was also estimated.
 ► Findings were based on a nationwide health in-
surance claims database covering all parts of 
Switzerland.
 ► Claims data did not provide information about quali-
ty as reflected in patients’ satisfaction, communica-
tion or decision- making.
ABSTRACT
Objectives The quality of ambulatory care in Switzerland 
is widely unknown. Therefore, this study aimed to 
evaluate the recently proposed quality indicators (QIs) 
based on a nationwide healthcare claims database and 
determine their association with the risk of subsequent 
hospitalisation at patient- level.
Design Retrospective cohort study.
Setting Inpatient and outpatient claims data of a large 
health insurance in Switzerland covering all regions and 
population strata.
Participants 520 693 patients continuously insured 
during 2015 and 2016.
Measures A total of 24 QIs were obtained by adapting 
the existing instruments to the Swiss national context 
and measuring at patient- level. The association between 
each QI and hospitalisation in the subsequent year was 
assessed using multiple logistic regression models.
Results The proportion of patients with good adherence 
to QIs was high for the secondary prevention of diabetes 
and myocardial infarction (glycatedhaemoglobin (HbA1c) 
control, 89%; aspirin use, 94%) but relatively low for 
polypharmacy (53%) or using potentially inappropriate 
medications (PIMs) in the elderly (PIM, 33%). Diabetes- 
related indicators such as the HbA1c control were 
significantly associated with a lower risk of hospitalisation 
(OR, 0.87; 95% CI, 0.80 to 0.95), whereas the occurrence 
of polypharmacy and PIM increased the risk of 
hospitalisation in the following year (OR, 1.57/1.08; 95% 
CI, 1.51 to 1.64/1.05 to 1.12).
Conclusions This is the first study to evaluate the recently 
presented QIs in Switzerland using nationwide real- life 
data. Our study suggests that the quality of healthcare, 
as measured by these QIs, varied. The majority of QIs, in 
particular QIs reflecting chronic care and medication use, 
are considered beneficial markers of healthcare quality as 
they were associated with reduced risk of hospitalisation in 
the subsequent year. Results from this large practical test 
on real- life data show the feasibility of these QIs and are 
beneficial in selecting the appropriate QIs for healthcare 
implementation in general practice.
INTRODUCTION
Measuring and monitoring healthcare 
quality is a necessary precondition to draw 
healthcare providers’ attention to the 
patients’ need and to determine potential 
areas for improvement. It is the basis for the 
evaluation and implementation of targeted 
interventions to optimise the effectiveness 
and safety of healthcare. Since several quality 
measures in the literature are developed for 
measuring healthcare quality in the hospital 
setting or only at practice- level, defining 
quality standards for primary care at patient- 
level is required.1–6 These standards ensure 
high- quality care in all countries and also 
facilitate the mutual learning process in 
global healthcare systems. National quality 
standards in primary care have been devel-
oped in several Western countries such as the 
UK,7 Germany,8–10 Australia11 and the Neth-
erlands.12 Considering the high healthcare 
expenditure (12.3% of the gross domestic 
product) in Switzerland, the country with the 
second highest life expectancy rate among 
the Organisation for Economic Co- operation 
and Development member states, the Swiss 
healthcare system is often considered as one 
of the most highly performing healthcare 
systems worldwide.13 However, the quality of 
Swiss healthcare is widely unknown. Switzer-
land does not have a national framework for 
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measuring healthcare quality in primary care, and instru-
ments for measuring and reporting quality of ambulatory 
services across Switzerland are insufficient.
Therefore, in 2016, we launched the Swiss Quality Indi-
cator for Primary Care (SQIPRICA) Project, which aimed 
to provide the first nationwide applicable and evidence- 
based set of indicators to measure the quality of primary 
care at patient- level in Switzerland.14 An independent 
multidisciplinary international expert group (the 
SQIPRICA group) rated the potential quality indicators 
(QIs) derived from international evidence sources,8–10 
and these QIs were adapted by the Swiss health system. 
Based on a consensus process, which explicitly included 
the patient perspective, a set of 24 QIs was identified. The 
QIs covered a wide range of domains in the Swiss primary 
healthcare setting, including general and disease- specific 
aspects such as drug safety, care for elderly, physicians’ 
efficiency and chronic disease management.
In this study, we measured the Swiss QIs in real- 
life settings and determined their association with an 
outcome at the patient- level. In contrast to evaluating the 
association between QIs and outcomes using aggregate 
data at the practice- level, analysis of individual patient- 
level data allows for the harmonisation of definitions and 
better adjustment of systematic differences of patient 
characteristics across subgroups.15 Moreover, the devel-
opment of valid measures of healthcare quality often 
requires a strong association between QIs and patient- 
relevant outcomes; however, most internationally existing 
studies on quality frameworks neglected it.16 17 One 
largely unique and good example is the experience from 
the pay- for- performance scheme, which has already been 
successfully implemented in the UK at the national level.18 
Additionally, previous studies evaluating quality measures 
were conducted only in selected care situations such as 
the treatment of symptomatic gallstones or the preven-
tion and management of cardiovascular diseases.1 3 19 20
The present study aimed to evaluate the recently 
presented set of 24 QIs in primary care based on a nation-
wide, patient- level healthcare claims database in one of 
the largest health insurances in Switzerland and to deter-
mine the association between each QI and the risk of 
hospitalisation in the subsequent year at patient- level.
METHODS
Study population and setting
We conducted a retrospective cohort study using the data 
from one of the largest health insurance companies in 
Switzerland, the Helsana Insurance Group. This patient- 
level database consists of anonymised pharmacy and 
medical and health services records of Helsana manda-
tory insured persons. Data can be considered repre-
sentative for the general population, since ~15% of the 
total population in Switzerland are included (covering 
all parts of the country). Every resident of Switzerland 
has the choice to be insured with Helsana health insur-
ance. According to the Swiss Health Law, every resident 
of Switzerland must be insured with a compulsory health 
insurance. The health insurers are privately organised 
and every Swiss resident can choose every health insurer. 
The obligatory health insurance provided is defined at 
the federal level and is similar for all health insurance 
companies; therefore, a high degree of generalisability 
of the data can be assumed. The longitudinal informa-
tion includes patients’ sociodemographic characteristics, 
healthcare plan, prescribed drugs (substance, dose), 
laboratory tests, outpatient consultations and hospital 
discharges including diagnoses according to the Inter-
national Classification of Diseases, 10th revision (ICD-
10). The high quality of the Helsana database has been 
previously validated, and data were widely used to investi-
gate the aspects of healthcare quality and several patient 
outcomes.21–24
Study subjects were considered eligible for inclusion in 
the study if they were aged ≥18 years in 2015 and contin-
uously covered by mandatory insurance at the Helsana 
Group between 1 January 2015 and 31 December 2016. 
Subjects living abroad, nursing home residents and 
patients with missing values (eg, incomplete cases) were 
excluded. The study included all healthcare invoices 
submitted to Helsana health insurance for reimburse-
ment; however, deductibles (ranging from 300 to 2500 
Swiss francs (CHF)) and cost sharing with 10% of the 
annual healthcare costs (up to 700 CHF) are obliga-
tory for every Swiss resident. In exchange for reduced 
premiums, the standard deductible of 300 CHF can be 
changed into a higher deductible of 500, 1500, 2000 or 
2500 CHF. Nevertheless, the included invoices represent 
nearly all total medical expenses of the mandatory insured 
patients at Helsana since the majority of patients chose 
a low deductible (300 to 500 CHF), depending on the 
corresponding sample for each QI calculation from 70% 
(total sample) to 88% (sample of patients ≥65 years and 
with ≥1 medication prescription). However, most patients 
with a high chosen deductible still submitted their bills 
to Helsana and only ~3% of the additional out- of- pocket 
payments were not send in (according to internal Helsana 
analysis). Since the proportion of unsubmitted invoices 
is very small in patients receiving medical services, the 
(cost) data were slightly underestimated.
The health insurance market is regulated by govern-
mental departments, and every health insurance company 
is obligated to guarantee insurance to every resident. The 
catalogue of health services reimbursed by basic manda-
tory health insurance is the same across the country and 
across all health insurance models.
Quality indicators
Development process
We used a total of 24 previously defined Swiss QIs at the 
patient- level. The QI development process was based on 
a comprehensive screening of existing clinical guidelines 
recommended by the German Association of Primary Care 
and Family Medicine (DEGAM, ‘Deutsche Gesellschaft für 
Allgemeinmedizin und Familienmedizin’), the German 
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National Disease Management Guidelines (NVL, ‘Natio-
nale VersorgungsLeitlinien’) and preexisting indicators 
from the QIs for Primary Care of the German Society of 
Quality Assurance (QISA, ‘Qualitätsindikatorensystem 
für die ambulante Versorgung’).8–10 In the absence of 
national guidelines, the German standards for quality 
in primary care were considered suitable for application 
since several structural similarities exist between the Swiss 
and German healthcare system (social health insurance 
system including a mix of public and private healthcare 
providers, German- speaking area). According to inter-
nationally established research methods for developing 
QIs in primary care, a six- step development process was 
implemented.25 In a first step, all recommendations for 
or against specific medical interventions of all currently 
existing DEGAM and NVL guidelines and all QISA quality 
indicators were extracted.8–10 As a second step, this list of 
potentially eligible items for QI was checked for opera-
tionalisability on Swiss health insurance claims data. In 
a third step, a multidisciplinary group of nine indepen-
dent experts (SQIPRICA Working Group) rated the list 
of potential QIs for relevance for public health, clarity of 
definition, influence on measured aspect of care, risk of 
undesired effects and strength of evidence. As a fourth 
step, in face- to face workshop consensus on a preliminary 
set of QIs was reached. The fifth step was a feasibility test 
(descriptive analysis) using claims data of 950 000 adult 
persons with Swiss basic mandatory health insurance. As 
a sixth step, the final set of QIs was defined in an addi-
tional workshop. The final set of 24 indicators covered 
general and specific aspects of the quality in primary 
care. The general domains included two categories: (1) 
general quality aspects (QI.1, QI.2) and (2) efficiency of 
healthcare (QI.3 to QI.7). The specific aspects comprised 
the following three domains: (1) drug safety (QI.8, 
QI.9), (2) care for the elderly (QI.10 to QI.13) and (3) 
chronic disease management/the medication therapy 
of acute cardiovascular events (disease- specific, QI.14 to 
QI.24). Details of the development process are described 
elsewhere.14
Measurements
The calculation of the single QIs was performed in 2015 
and can be described as follows: QI.1 and QI.2 relate to 
the general aspects and were thus calculated in the total 
sample. For the calculation of QI.3 to QI.24, additional 
specific inclusion criteria were applied: QI.3, QI.8 and 
QI.9 relate to patient subgroups with ≥1 prescription of 
each relevant medication class according to the WHO 
Anatomical Therapeutic Chemical (ATC) groups:26 
proton pump inhibitors (PPIs), statins, angiotensin II 
(ATII) antagonists, ACE inhibitors, anxiolytics/sedatives/
hypnotics and non- steroidal anti- inflammatory drugs 
(NSAIDs). QI.3 calculates the drug costs of the given ATC 
group divided by the sum of the received defined daily 
dose (DDD) per person/year. Considering that the distri-
bution of costs was heavily skewed and that cost figures 
could not easily be translated in good or poor quality of 
care, we cut the range of costs into four (QI.3) and six 
(QI.2) equally populated cost groups (with one excep-
tion: since the high costs in QI.2 were significantly preva-
lent, we divided it into two high- cost groups; the groups of 
QI.2 were not equally distributed). QI.4 and QI.5 relate 
to the efficiency of general medication prescriptions; 
thus, they were calculated in a subsample of persons with 
≥1 medication prescriptions irrespective of the drug class. 
QI.4 calculates the occurrence of prescribed generics 
versus the receipt of a prescribed original product with 
increased co- payment (20% vs 10%).27 QI.5 reflects the 
existence of prescribed inefficient me- too medications 
including analogue drugs with no or only marginal differ-
ences to already launched drugs or drugs with unclear 
therapeutic value. The assignment was based on classifi-
cations developed by Fricke and Klaus.28 29 QI.6 and QI.7 
measure the number of different primary care physicians 
or specialists and were calculated in persons who had ≥1 
physician (primary care/specialist physician) consulta-
tion. The quality of care for the elderly is displayed in 
QI.10 to QI.13 and was thus assessed in the subsample of 
persons aged ≥65 years. QI.10 and QI.11 reflect the drug 
safety in elderly patients with ≥1 medication prescrip-
tion: QI.10 measures ‘polypharmacy’ (>5 different drug 
prescriptions in ≥1 quarter per patient/year) and QI.11 
‘potentially inappropriate medications (PIM)’ (≥1 PIM 
prescription in ≥1 quarter per patient/year). PIM was 
calculated based on ATC codes, the PRISCUS list (Latin 
for ‘time- honoured’), and Beers criteria and included 
medications that had to be avoided in elderly patients 
due to evidence of increased complications and poor 
outcomes.30 31 Another QI regarding care for the elderly 
was the influenza vaccination, which is displayed in 
QI.12. To determine the presence of hospitalisation for 
fractures near the pelvic joint (ICD-10 ‘S72.0x’, QI.13), 
the presence of ≥1 comorbidity (measured as pharmacy- 
based cost group, PCG) was applied as an additional crite-
rion.32 33 QI.14 and QI.15 assessed the long- term therapy 
of systemic corticosteroids in two sequential quarters and 
the disease- specific hospitalisation (ICD-10 ‘J.44/45’) 
in patients with respiratory diseases (presence of the 
corresponding PCG). QI.16 to QI.20 relate to patients 
with diabetes mellitus (measured as PCG ‘diabetes’) and 
evaluated the annual control of glycatedhaemoglobin 
(HbA1c), lipid and kidney values, the eyes and the occur-
rence of hospitalisation. The secondary prevention of 
myocardial infarction (ICD-10 ‘I.21’) and stroke/tran-
sient ischaemic attack (TIA, ICD-10 ‘I.64’, ‘G.45’) with 
the use of acetylsalicylic acid (aspirin, ASS) and statins in 
the 12 months following hospital discharge was reflected 
in QI.21 to QI.24. A detailed description of each indicator 
is provided in online supplementary table S1.
Baseline covariates and outcome
Several patient characteristics such as age, gender, region 
of residence (urbanisation, language), type of health 
insurance plan (deductibles ‘low: 300 to 500 CHF’ vs 
‘high: >500 CHF’, supplementary/private insurance) and 
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proxies for health status were obtained from the database 
in 2015. Patients’ individual health status was approxi-
mated by the number of patients’ chronic diseases and 
the incurred healthcare costs in the previous year (2014). 
According to the WHO ATC classification system, a total 
of 22 diseases were identified using the well- established 
pharmacy- based mapping approach for chronic condi-
tions (PCGs).32 33 Conditions comprised bone diseases 
(osteoporosis), cancer, cardiovascular diseases (including 
hypertension), dementia, diabetes mellitus, epilepsy, glau-
coma, gout/hyperuricaemia, HIV infection, hyperacidity- 
related disorders, hyperlipidaemia, iron deficiency 
anaemia, migraine, pain, Parkinson’s disease, psycho-
logical disorders, psychoses, respiratory illness, rheuma-
tological conditions, thyroid disorders and tuberculosis. 
In the absence of systematically recorded clinical diag-
noses in the entire Swiss outpatient setting, this mapping 
approach provides a direct measure of the treated chronic 
conditions and is a commonly used and reliable method 
to identify chronically ill patients in administrative data-
bases.34 35 The summarised measure ‘number of chronic 
conditions’ was categorised into four groups (0 to 1, 2 to 
3, 4 to 5, ≥6). Healthcare costs incurred in the previous 
year were calculated and considered as surrogate for the 
medical history of the patients reflecting disease severity. 
They include all costs reimbursed by Swiss basic manda-
tory health insurance, excluding cost sharing of cantonal 
authorities and insured person (co- payments, deduct-
ibles). The outcome of interest was all- cause hospitalisa-
tion in 2016 (follow- up), defined as an overnight hospital 
stay within the year.
Statistical analysis
Sociodemographic variables and other baseline charac-
teristics of the total study sample were summarised using 
descriptive statistics. Categorical variables were presented 
as percentages and continuous variables as means (SD). 
According to the definition of QIs, we computed the 
overall 16 subgroups to determine the percentage of 
patients meeting the corresponding QI. To validate the 
calculated QIs, for each QI, a multiple logistic regres-
sion model was performed to assess the independent 
association between QIs at baseline (2015) and all- cause 
hospitalisation at follow- up (2016); with exception of 
QIs that are already clearly utilisation measures (QI.1, 
QI.13, QI.15, QI.18). All performed regression models 
were controlled for the following patient characteristics: 
gender, age, region of residence, type of health insurance 
plan, proxies for health status (number of chronic condi-
tions, healthcare costs in the previous year (2014)). The 
selection of the included independent variables was based 
on the current Swiss risk equalisation model.36 Besides 
age and gender, the regional variables were also included 
since the Swiss healthcare system is regulated at regional 
level (by canton); additionally, proxies for health status 
were defined as covariables because they strongly influ-
ence health outcomes.21 We included the summarised 
measure ‘number of chronic conditions’ (categories: 0 to 
1, 2 to 3, 4 to 5, ≥6) as control variable because it reflects a 
simple index for chronic disease status. In literature, this 
kind of indexes is a very helpful and effective instrument 
to measure patients’ health status and to reflect co- mor-
bidity status.21 Using a comprehensive morbidity measure 
in every QI- analysis increased the comparability of our QI 
results.
Moreover, all regression models were separately 
performed for high- risk beneficiaries which were defined 
as follows: (1) Patients suffering from at least two chronic 
conditions simultaneously, and (2) Patients with at least 
two chronic conditions and high costs. The cut- off point of 
two conditions was used because studies have shown that 
the co- occurrence of two of more (chronic) conditions 
within one patient has a high impact on future adverse 
health outcomes such as hospitalisation.37 38 Patients with 
high costs were defined as the top 20% of patients incur-
ring the highest healthcare costs in the previous year.39 40 
We did not correct for multiple comparisons, since the 
selection of the QIs was theoretically based (derived from 
German national guidelines and adapted to the Swiss 
system by the SQIPRICA Working Group), and did not 
depend on the observed results. All 24 QIs were statisti-
cally tested and all results were reported. The QIs reflect 
different aspects of the healthcare quality and exist 
independently of each other. Statistical analyses were 
performed using the statistical programme R V.3.5.0 (R 
Development Core Team 2018). Significance was deter-
mined at a level of 0.05.
Patient and public involvement
Since we analysed already recorded health insurance 
claims data, patients or the public were not involved.
RESULTS
A total of 520 693 patients were eligible for analysis in 
the baseline year (2015). Table 1 shows the patient char-
acteristics of our study cohort. There were slightly more 
women (53%) than men (47%), and the mean age was 
54 years. Regarding the geographical distribution, most 
persons lived in urban regions (66%) and approximately 
a quarter of the population in the Latin- speaking areas of 
Switzerland. Almost 30% of the sample chose a deduct-
ible class greater than 500 CHF, and approximately a fifth 
chose a supplementary/private health insurance plan. 
The annual mean healthcare costs of basic mandatory 
health insurance per patient amounted to 4848 CHF in 
the previous year. Moreover, 41% of the study population 
had two or more chronic conditions as assessed using 
PCGs.
Table 2 presents the number of persons in the various 
subpopulations who required the calculation of the Swiss 
QIs. We defined the number of patients with respiratory 
disease and diabetes mellitus and revealed a prevalence 
of approximately 10% and 7%, respectively. When the 
analytical sample was based on patients with a specific 
event (myocardial infarction, stroke or TIA), the number 
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  Male 244 196 (46.9)
  Female 276 497 (53.1)
  Mean age±SD 53.5±19.1
Age groups (in years)
  ‘18–30’ 73 864 (14.2)
  ‘31–40’ 72 200 (13.9)
  ‘41–50’ 84 720 (16.3)
  ‘51–60’ 90 412 (17.4)
  ‘61–70’ 85 023 (16.4)
  ‘71–80’ 70 074 (13.5)
  ‘81–90’ 38 653 (7.4)
  ‘≥91’ 5747 (1.1)
Region of residence
  Urban/rural region
  Urban 345 733 (66.4)
  Intermediary (dense peri- urban area 
and rural centres)
105 641 (20.3)
  Rural 69 319 (13.3)
Language region
  German- speaking/French- speaking 
area
392 953 (75.5)
  Latin- speaking area 127 740 (24.5)
Health insurance plan
Deductible class
  Low (≤500 Swiss Francs) 365 383 (70.2)
  High (>500 Swiss Francs) 155 310 (29.8)
Insurance coverage
  Mandatory insurance (only) 416 098 (79.9)
  Mandatory and/or supplementary 
insurance
104 595 (20.1)
Proxies for health status
Number of chronic conditions
  0–1 308 018 (59.2)
  2–3 132 454 (25.4)
  4–5 57 753 (11.1)
  ≥6 22 468 (4.3)
  Healthcare costs in the previous year 
(mean±SD) in Swiss Francs
4848±9833
Table 2 Patient inclusion criteria relevant for the calculation 





Inclusion criteria (for QI 
calculation)
Efficiency and drug safety
  ≥1 primary care (PC) 
physician consultation
QI.6 368 805 (70.8)
  ≥1 PC or specialist 
physician consultation
QI.7 441 424 (84.8)
  ≥1 prescription of any 
medication
QI.4, QI.5 438 116 (84.1)
  ≥1 prescription of 
proton pump inhibitors
QI.3 133 475 (25.6)
  ≥1 prescription of 
statins
QI.3 79 217 (15.2)
  ≥1 prescription 
of angiotensin II- 
antagonists
QI.3 34 945 (6.7)
  ≥1 prescription of ACE 
inhibitors
QI.3 33 085 (6.4)
  ≥1 prescription of 
anxiolytics, sedatives 
or hypnotics
QI.8 88 233 (16.9)
  ≥1 prescription of 
non- steroidal anti- 
inflammatory drugs
QI.9 195 721 (37.6)
Care for elderly
  ≥65 years old QI.12 166 053 (31.9)
  ≥65 years old and ≥1 
prescription of any 
medication
QI.10, QI.11 146 618 (28.2)
  ≥65 years old and ≥1 
chronic condition
QI.13 117 529 (22.6)
Diseases
  Respiratory disease QI.14, QI.15 51 246 (9.8)
  Diabetes mellitus QI.16–20 36 715 (7.1)
  Myocardial infarction QI.21, QI.22 1284 (0.2)
  Stroke or transient 
ischaemic attack
QI.23, QI.24 518 (0.1)
QI, quality indicator.
of eligible patients was 1284 and 518, respectively. Online 
supplementary table S2 describes the outcome (hospital-
isation) for each subsample used for the calculation of 
the QIs. Approximately 15% of the patients with at least 
one medication prescription in the baseline year (2015) 
were hospitalised in the following year (2016), whereas 
the proportion of hospitalised patients receiving specific 
medications such as PPIs, statins and ATII antagonists was 
higher (22%).
Table 3 depicts the 1- year prevalence of QIs measuring 
the general aspects and efficiency. QI.1 measures emer-
gency hospital admission that contributes a rate of 4% in 
the total analytical sample. QI.2 divides the sample into six 
groups according to their annual medication costs (total): 
more than half of the sample incurred 420 CHF or less 
in the year 2015. Regarding the efficiency of medication 
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QI.1 From total population
Emergency hospital admission 22 190 (4.3)
QI.2 From total population
Medication costs (in Swiss Francs, 
CHF and classes)
Class 1 (CHF 0) 82 577 (15.9)
Class 2 (CHF 1–113) 94 856 (18.2)
Class 3 (CHF 114–420) 109 382 (21.0)
Class 4 (CHF 421–1188) 117 948 (22.7)
Class 5 (CHF 1189–2165) 58 827 (11.3)
Class 6 (CHF ≥2166) 57 103 (11.0)
Efficiency
QI.3 Costs per DDD in specific ATC 
groups
From subgroup: ≥1 prescription of 
proton pump inhibitors (PPI)
Costs per DDD PPI (in Swiss 
Francs, CHF and classes)
Class 1 (CHF 0.40–0.71) 33 810 (25.3)
Class 2 (CHF 0.72–0.94) 33 951 (25.4)
Class 3 (CHF 0.95–1.23) 33 799 (25.3)
Class 4 (CHF ≥1.24) 31 915 (23.9)
From subgroup: ≥1 prescription of 
statins
Costs per DDD statins (in Swiss 
Francs, CHF and classes)
Class 1 (CHF 0.18–0.54) 19 602 (24.7)
Class 2 (CHF 0.55–0.72) 19 823 (25.0)
Class 3 (CHF 0.73–1.18) 20 207 (25.5)
Class 4 (CHF ≥1.19) 19 585 (24.7)
From subgroup: ≥1 prescription of 
angiotensin II- antagonists (ATII)
Costs per DDD ATII (in Swiss 
Francs, CHF and classes)
Class 1 (CHF 0.16–0.36) 8813 (25.2)
Class 2 (CHF 0.37–0.51) 8940 (25.6)
Class 3 (CHF 0.52–0.69) 8913 (25.5)
Class 4 (CHF ≥0.70) 8279 (23.7)
From subgroup: ≥1 prescription of 
ACE inhibitors
Costs per DDD ACE (in Swiss 
Francs, CHF and classes)
Class 1 (CHF 0.11–0.23) 8404 (25.4)
Class 2 (CHF 0.24–0.31) 8685 (26.3)
Class 3 (CHF 0.32–0.38) 7794 (23.6)
Class 4 (CHF ≥0.39) 8202 (24.8)
Continued
QI.4 From subgroup: ≥1 medication 
prescription
Prescription of generics 93 473 (21.3)
QI.5 From subgroup: ≥1 medication 
prescription
Prescription of inefficient me- too 
medications
298 328 (68.1)
QI.6 From subgroup: ≥1 primary care 
(PC) physician consultation
Number of different PC physicians 
consulted
1 280 291 (76.0)
2 70 414 (19.1)
≥3 18 100 (4.9)
QI.7 From subgroup: ≥1 primary 
care (PC) or specialist physician 
consultation
Number of different specialist 
physicians consulted
0 99 313 (22.5)
1 127 327 (28.8)
2 88 896 (20.1)
3 55 292 (12.5)
≥4 70 596 (16.0)
ATC, anatomical therapeutic chemical; DDD, defined daily dose; QI, 
quality indicator.
Table 3 Continued
prescription, the costs per DDD of PPIs and statins were 
considerably higher than the costs of ATII antagonists 
and ACE inhibitors (QI.3). A generic medication was 
prescribed to approximately 20% of the patients (QI.4). 
Approximately 70% of the drug users were prescribed an 
inefficient me- too medication according to the classifica-
tion of Fricke and Klaus (QI.5). QIs attributed to patients’ 
consultation behaviour revealed that only 5% consulted 
three or more different primary care physicians (QI.6) 
and that, in contrast, 16% had consultations with at least 
four different specialist physicians (QI.7).
Table 4 displays the prevalence of QIs related to drug 
safety, care for the elderly and disease- specific QIs. QI.8 
and QI.9 indicate the risk for overuse of anxiolytics/seda-
tives/hypnotics and NSAIDs, respectively. Approximately 
a quarter of each medication user group received three 
or more packages. QIs covering the aspects of care for 
the elderly (QI.10 to QI.13) revealed a relatively high 
proportion of persons aged ≥65 years who received poly-
pharmacy (QI.10, 53%) and PIM (QI.11, 33%), whereas 
a modest percentage of elderly patients received an influ-
enza vaccination (QI.12, 18%) or a hospitalisation for 
fracture near the pelvic point (QI.13, 0.3%). Regarding 
chronic disease management, a considerable number of 
patients with diabetes mellitus received guideline- based 
healthcare (QI.16, HbA1c: 89%; QI.17, ophthalmological 
control: 50%; QI.19, control of lipid values: 64%), and 
7Huber CA, et al. BMJ Open 2020;10:e032700. doi:10.1136/bmjopen-2019-032700
Open access
Table 4 Quality indicators (QI.8–24), part 2: specific 





QI.8 From subgroup: ≥1 prescription of 
anxiolytics, sedatives or hypnotics
Number of prescriptions
1 49 728 
(56.4)
2 15 490 
(17.6)
≥3 23 015 
(26.1)
QI.9 From subgroup: ≥1 prescription 
of non- steroidal anti- inflammatory 
drugs
Number of prescriptions
1 108 320 
(55.3)
2 44 700 
(22.8)
≥3 42 701 
(21.8)
Care for elderly
QI.10 From subgroup: ≥65 years and ≥1 
medication prescription
Polymedication 78 156 
(53.3)






QI.12 From subgroup: ≥65 years
Influenza vaccination 30 208 
(18.2)
QI.13 From subgroup: ≥65 years and ≥1 
chronic condition




QI.14 From subgroup: patients with 
respiratory disease
Long- term therapy of 
corticosteroids
1106 (2.2)
QI.15 From subgroup: patients with 
respiratory disease
Disease- specific hospitalisation 709 (1.4)
QI.16 From subgroup: patients with 
diabetes mellitus
HbA1c control 32 770 
(89.3)
Continued
QI.17 From subgroup: patients with 
diabetes mellitus
Ophthalmological control 18 493 
(50.4)
QI.18 From subgroup: patients with 
diabetes mellitus
Hospitalisation 7303 (19.9)
QI.19 From subgroup: patients with 
diabetes mellitus
Control of lipid values 23 535 
(64.1)
QI.20 From subgroup: patients with 
diabetes mellitus
Control of kidney values 17 345 
(47.2)
QI.21 From subgroup: patients with 
myocardial infarction
Receiving ASS within 12 months 
after event
1210 (94.2)
QI.22 From subgroup: patients with 
myocardial infarction
Receiving statins within 12 months 
after event
1127 (87.8)
QI.23 From subgroup: patients with 
stroke or TIA
Receiving ASS within 12 months 
after event
391 (75.5)
QI.24 From subgroup: patients with 
stroke or TIA
Receiving statins within 12 months 
after event
386 (74.5)
ASS, aspirin; HbA1c, glycated haemoglobin; QI, quality indicator; 
TIA, transient ischaemic attack.
Table 4 Continued
only a small number of patients with respiratory diseases 
underwent a long- term therapy of corticosteroids (QI.14, 
2%) or were hospitalised due to disease- specific compli-
cations (QI.15, 1%). ASS and statins were administered in 
the majority of patients after an acute myocardial infarc-
tion (QI.21 and QI.22, ~90%) and in three- quarters of 
the patients with stroke or TIA (QI.23 and QI.24, ~75%).
Figure 1 displays the multivariate regression results esti-
mating the association between the QIs measuring general 
and efficiency aspects and patients’ all- cause hospitalisa-
tion risk in the following year. After adjusting for sociode-
mographic characteristics and proxies for health status, 
all QIs except for QI.3 (categories of costs per DDD of 
relevant drug classes) indicated validity since their pres-
ence in a patient was associated with statistically signifi-
cant increased risk of hospitalisation in the following year. 
Analysis of QI.2 showed a significant positive association: 
the higher the medication costs, the higher the risk of 
hospitalisation in the following year. Costs per DDD in 
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Figure 1 Quality indicators (QI.2–7), general aspects. ATC, anatomical therapeutic chemical; ATII, angiotensin II; DDD, defined 
daily dose; PPI, proton pump inhibitor.
selected ATC drug classes were not relevantly associated 
with hospitalisation risk (QI.3). Prescription of generics 
(QI.4) and prescription of me- too medications according 
to the classification of Fricke and Klaus (QI.5) indicated 
a slight increase in hospitalisation risk (OR, 1.09/1.17; 
95% CI, 1.07 to 1.12/1.14 to 1.20). Additionally, the more 
primary care physicians consulted (QI.6), the higher the 
risk of hospitalisation in the following year, which was 
similar for the number of specialist physicians consulted 
(QI.7).
Figure 2 displays the estimates for QIs relating to 
specific aspects of care. The number of prescriptions of 
anxiolytics, sedatives or hypnotics (QI.8) was not associ-
ated with hospitalisation in the following year. In contrast, 
the more prescriptions of NSAIDs a patient received at 
baseline (QI.9), the higher was his or her probability 
of hospitalisation in the following year (OR, 1.05/1.12; 
95% CI, 1.02 to 1.09/1.08 to 1.15). Moreover, the indi-
cators displaying the quality of care for the elderly, such 
as receiving polypharmacy (QI.10) or PIM (QI.11), were 
statistically significantly associated with the odds of hospi-
talisation (OR, 1.57/1.08; 95% CI, 1.51 to 1.64/1.05 to 
1.12). Patients who had received an influenza vaccination 
(QI.12) were more likely to be hospitalised than were 
patients who did not receive an influenza vaccination. 
Long- term therapy of systemic corticosteroids (QI.14) in 
patients with respiratory disease was strongly associated 
with hospitalisation in the following year (OR, 1.56; 95% 
CI, 1.37 to 1.77). Chronically ill patients had lower rates 
of hospitalisations when they received the measures of 
secondary prevention. In patients with diabetes, HbA1c 
control (QI.16) and control of lipid values at baseline 
(QI.19) were statistically significantly associated with a 
decreased risk of hospitalisation in the following year 
(OR, 0.87/0.82; 95% CI, 0.80 to 0.95/0.77 to 0.86). 
Ophthalmological control (QI.17) was not associated 
with hospitalisation risk. In contrast, control of kidney 
values (QI.20) was associated with a slight increase of the 
odds of hospitalisation. With respect to the secondary 
prevention of stroke or TIA, patients after stroke or TIA 
who received statins (QI.24) were less likely to be hospi-
talised in the following year than were non- users of statins 
(OR,0.59; 95% CI, 0.36 to 0.97).
Online supplementary tables S3,S4 show the results of 
regressions for high- risk beneficiaries defined as patients 
with ≥2 chronic conditions and patients with high costs 
and ≥2 chronic conditions. Overall, the regression results 
were quite similar to the results based on the total sample, 
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Figure 2 Quality indicators (QI.8–24), specific aspects. All regression models were controlled for: age, sex, region of residence 
(rural/urban), Latin- speaking area (yes/no), deductible class (low/high), supplementary/private insurance (yes/no), number of 
chronic conditions, healthcare costs in the previous year (in cost classes). ASS, aspirin; HbA1c, glycated haemoglobin; NSAIDs, 
non- steroidal anti- inflammatory drugs; PIM, potentially inappropriate medication.
but with some larger and some smaller ORs in these high- 
risk groups. Especially, QIs reflecting drug safety in elderly 
patients were stronger associated with the hospitalisation 
risk in both high- risk groups: the OR of polypharmacy 
(QI.10) and PIM (QI.11) were larger than in the high- risk 
groups compared with the total sample (polypharmacy: 
OR, 1.57; 95% CI, 1.51 to 1.64 (total) vs OR, 1.71/1.94; 
95% CI, 1.65 to 1.77/1.82 to 2.07 (high- risk); PIM: OR, 
1.08; 95% CI, 1.05 to 1.12 (total) vs OR, 1.15/1.17; 95% 
CI, 1.11 to 1.19/1.11 to 1.23 (high- risk)). Additionally, in 
contrast to the total sample the high- risk group analysis 
showed a significant association between ≥3 prescrip-
tions of anxiolytics, sedatives or hypnotics (QI.8) and the 
hospitalisation risk in the following year (OR, 0.96; 95% 
CI, 0.92 to 1.00 (total) vs OR, 1.07/1.06; 95% CI, 1.02 to 
1.11/1.01 to 1.12 (high risk)). Furthermore, ORs of the 
number of different primary care physicians consulted 
(QI.6) were larger in the high- risk groups than in the 
total sample (OR, 1.20; 95% CI, 1.15 to 1.24 (total) vs OR, 
1.25/1.23; 95% CI, 1.19 to 1.30/1.16 to 1.31 (high- risk)). 
On the other side, a few ORs were smaller or even not 
significant in the high- risk group analysis. For example, 
compared with the regression results of the total sample 
indicators reflecting medication costs such as QI.2 and 
QI.3 showed no significant association with the future 
hospitalisation risk in the high- risk group analysis (eg, 
QI.2 (class 6): OR, 2.59, 95% CI; 2.46 to 2.72 (total) vs 
OR, 0.82/0.001; 95% CI, 0.07 to 9.34/0.92 to 1.11)).
DISCUSSION
To the best of our knowledge, this is the first study that 
evaluated a large set of evidence- based QIs at a national 
level and determined the association between QI results 
and patient- relevant outcome measures. This is an 
important step toward proving data on healthcare quality 
and quantifying and comparing different quality aspects. 
The study revealed a clinically relevant and, in most cases, 
statistically significant association between the presence 
of QIs at patient- level and the risk of hospitalisation.
The previously presented set of 24 QIs that were based 
on evidence from the German guidelines and adapted 
to the Swiss healthcare system, resulting in the establish-
ment of the multidisciplinary SQIPRICA Working Group 
panels, includes process indicators (16), healthcare cost 
indicators (4) and outcome indicators (4). In general, a 
broad spectrum of QIs indicated a close association with 
patient outcome. In particular, the indicators relating to 
chronic illness care, care for the elderly, medication use 
and relatively simple measures of coordination (number 
of healthcare physicians) are considered beneficial 
predictors of a beneficial outcome. Diabetes process and 
outcome indicators such as the annual control of HbA1c 
were significantly associated with a lower risk of hospital-
isation in the following year. This finding is strongly consis-
tent with the results of previous investigations showing a 
clear decrease in hospital admissions by improvements 
in quality of diabetic management.41 42 Moreover, the 
compliance to indicators reflecting the quality of care in 
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patients with respiratory diseases showed a positive associ-
ation with outcomes, which is consistent with the result of 
previous studies.43 44
Furthermore, the present study emphasises the 
relevance of adverse drug reactions in the context of 
healthcare quality. Consistent with previous studies, poly-
pharmacy and PIM were highly prevalent in patients aged 
65 years or older, leading to an increased risk of hospi-
talisation and indicating intolerances and drug interac-
tions among the elderly.22 45 46 Moreover, analyses of the 
high- risk groups showed a stronger association between 
polypharmacy or PIM and the hospitalisation risk in 
the following year compared with the total sample. This 
finding indicates the very high risk of adverse drug reac-
tions in vulnerable patient groups and stresses that the 
awareness of drug safety should be urgently increased 
especially in high- risk patients suffering from multi-
morbidity and/or patients with high healthcare costs as 
indicator for a high burden of disease.47 48 Additionally, 
estimates referring to the different physician consulta-
tions revealed a relatively simple, but potent, predictor of 
outcome, which is consistent with the results of previous 
studies, indicating a better coordination in terms of the 
benefit of continuity of care together with improved 
quality of care.49 50 Interestingly, compared with ASS use, 
the use of statins after stroke or TIA was found to be highly 
protective (QI.24). Generally, for QIs relating to clinical 
events, the number of cases tends to be significantly small 
in a small country such as Switzerland for the comparison 
of practices, physician networks or regions (QI.21–24).
Additionally, the influenza vaccination was not positively 
associated with the outcome, which can be explained as 
follows: First of all, there is only a small proportion of 
patients who received an influenza vaccination (18%), 
which may reflect the inconsistent practice resulting from 
unclear medical recommendations in Switzerland. More-
over, we assume that the patients with influenza vaccina-
tion had a higher risk of hospitalisation since they reflect 
the sample with a high burden of disease. The results 
are likely to depict a selection of highly morbid patients. 
This explanation is in line with current study results from 
Switzerland which showed that influenza vaccination was 
significantly associated with a low self- reported health 
status and the occurrence of several chronic diseases such 
as diabetes mellitus and lung diseases (bronchial asthma, 
chronic bronchitis and emphysema).51
Prescription of generics (QI.4) and prescription of 
me- too medications (QI.5) indicated a slight increase in 
hospitalisation risk. We assume that these two measures 
are not useful in the Swiss healthcare system. The opera-
tionalisation of these QIs is not suitable since the two indi-
cators are not markers for generics but rather for patient 
characteristics. Both were imported from Germany, where 
the market and the incentives for generics are different, 
and the definition of me- too drugs is also market- specific. 
Further research is needed to refine indicators reflecting 
inefficient medication prescriptions. In contrast, costs 
per DDDs do not seem to be negatively associated with 
quality, which is considered a positive finding when 
increasing the cost- efficiency of medication prescription.
Strengths and limitations
The present study has several strengths. First, it responds 
to the current public debates on quality assurance in 
ambulatory care. Second, this study evaluated the given 
Swiss adapted quality indicators for the first time in the 
Swiss healthcare setting and provides new insights for the 
stakeholder. Furthermore, the study findings might there-
fore contribute to encourage researchers to also evaluate 
their indicators and to publish the results. This might also 
help to increase acceptance of indicators and to increase 
transparency related to the development and evaluation 
of these measures. Third, the study was based on a large 
real- life data set of a broad spectrum of patients from all 
parts of Switzerland. Claims are available nationwide and 
underlie a standardised format and relatively high level of 
data control mechanisms. Fourth, the present project was 
based on a triangular approach consisting of (1) evidence 
from highly reliable sources, (2) adaptation to the local 
context and inclusion of the patient perspective and (3) 
data- based evaluation. However, several limitations also 
need to be considered. First, our study population was 
not entirely representative of the general Swiss popula-
tion and had minor differences regarding sex, age groups 
and the region of residence, but the Helsana population 
covers insurers from all parts of Switzerland and includes 
all age groups and patient subgroups.52 53 A recently 
published Helsana study could show that the Helsana 
population is only slightly older (mean percentage differ-
ence (mean diff.) of all age groups: 0.04%), had a slightly 
higher percentage of women (diff.: 0.4%) and very 
slightly varied regarding overrepresentation/underrep-
resentation of persons in only a few cantons (eg, canton 
Geneva; mean diff. of all cantons: 0.64%).52 Second, 
considering the nature of claims data information about 
quality as reflected in patients’ satisfaction, communi-
cation and decision- making were not addressed. Third, 
clinical diagnoses from the outpatient setting were not 
available for adjustment in multivariate models. However, 
we used the well- established PCGs as proxies for ambula-
tory diagnoses to adjust for the differences in the risk of 
hospitalisation. Fourth, our results displayed the quality of 
healthcare from the mandatory health insurance perspec-
tive and did not include data from supplementary private 
insurance data. However, the basic mandatory insurance 
catalogue in Switzerland covers all services used for the 
present analysis. Finally, although we carefully adjusted 
for all variables that might interfere with hospitalisation 
risk available in our database, it is not possible to verify 
the causal association due to the cohort study design.
Implications for future studies
Several future research issues can be derived from our 
findings: Contrary to clinical events or relatively rare 
situations, future studies should predominately focus on 
highly prevalent chronic conditions (additional QIs). 
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For the first attempts of implementation, it seems to be 
reasonable to focus on QIs reflecting chronic care and 
drug safety. Future QIs that focus on coordination and 
continuity of care would be also highly relevant. More-
over, the set of QIs might be supplemented by QIs derived 
from other sources such as the smarter medicine initiative. 
Additionally, the aspect of intersectoral problems, care 
coordination and interdisciplinary collaboration is not yet 
explicitly targeted in the current set of QIs. However, the 
issue is of increasing importance and a matter of ongoing 
political discussion.54 Additionally, the present study indi-
cates that QIs focussing on specific clinical events such as 
myocardial infarction or stroke are limited by relatively 
small numbers of cases, which is even more relevant when 
small units such as care regions or specific patient strata 
should be monitored. Future studies are required to 
identify additional QIs targeting highly prevalent chronic 
conditions or clinical situations. Moreover, most of the 
indicators in the current set focussed on processes. Future 
studies are required to identify additional QIs measuring 
the quality of outcomes. Additionally, certain QIs such as 
influenza vaccination should be improved, supplemented 
or refined. Finally, future studies should evaluate if and 
how QIs derived from health insurance claims are supple-
mented with QIs derived from other sources (patient 
surveys, official statistics).
CONCLUSIONS
This is the first practice test of a previously proposed 
set of QIs that are principally available across Switzer-
land as they are based on the standardised format of 
Swiss health insurance claims data. The study revealed 
that constructing these indicators is feasible. Quality as 
measured by these QIs varies. The majority of QIs, in 
particular QIs reflecting chronic care and medication use, 
are considered beneficial markers of quality of care as they 
were associated with reduced risk of hospitalisation in the 
subsequent year. Furthermore, the study indicates that 
some QIs, such as influenza vaccination, require reevalu-
ation and further refinement. In conclusion, the study is 
beneficial in identifying the starting points for initiatives 
to improve the quality of primary care in Switzerland. It 
provides further evidence when utilising the health insur-
ance claims data available across all regions, healthcare 
settings and patient populations for assessing, monitoring 
and exchanging data on the quality of primary care.
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